Final Exam - NURS6521 / NURS 6521 (Latest
) : Advanced Pharmacology -
Walden University
SECTION I: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–30)
1. A 72-year-old patient with cirrhosis and albumin of 2.1 g/dL is prescribed a highly protein-
bound drug. The nurse practitioner should anticipate which pharmacokinetic alteration?
A. Decreased free drug concentration
B. Increased volume of distribution
C. Increased free (active) drug concentration
D. Prolonged drug half-life due to increased protein binding
Correct Answer: C
Rationale: Albumin is the primary binding protein for many acidic drugs. In
hypoalbuminemia (e.g., cirrhosis), fewer binding sites are available, leading to an increased
fraction of unbound (free) drug. Only free drug is pharmacologically active and capable of
producing therapeutic and toxic effects. This increases the risk of toxicity even at standard
doses. Volume of distribution may increase or decrease depending on the drug, but the most
direct and predictable consequence is elevated free drug levels.
2. A drug has a half-life of 8 hours. Approximately how long will it take to reach steady-state
concentration with a constant-rate infusion?
A. 8 hours
B. 16 hours
C. 32–40 hours
D. 72–80 hours
Correct Answer: C
Rationale: Steady state is reached after approximately 4–5 half-lives. With a half-life of 8
hours, steady state occurs in 4 × 8 = 32 hours to 5 × 8 = 40 hours. At steady state, the rate of
drug administration equals the rate of drug elimination. Understanding this principle is essential
for determining appropriate dosing intervals and timing of serum drug level monitoring.
,3. Which statement most accurately describes a competitive antagonist?
A. It binds irreversibly to the receptor, permanently inactivating it
B. It binds to the same receptor site as the agonist and can be overcome by increasing agonist
concentration
C. It binds to an allosteric site and enhances the agonist's effect
D. It produces a submaximal response compared to a full agonist
Correct Answer: B
Rationale: Competitive antagonists reversibly bind to the same receptor site as the agonist,
preventing agonist binding. Because the binding is reversible, increasing the concentration of
the agonist can displace the antagonist and restore the maximal response. This is in contrast to
noncompetitive antagonists, which bind irreversibly or at allosteric sites and cannot be
overcome by increasing agonist concentration. Option D describes a partial agonist, not an
antagonist.
4. A patient is a poor metabolizer of CYP2D6 substrates. Which medication would pose the
greatest risk of toxicity at standard doses?
A. Metformin
B. Codeine
C. Amoxicillin
D. Furosemide
Correct Answer: B
Rationale: Codeine is a prodrug that requires CYP2D6-mediated conversion to its active
metabolite, morphine. In poor metabolizers, codeine is not effectively converted, leading to
inadequate analgesia. However, the question specifically asks about toxicity risk. For CYP2D6
substrates that are active drugs (not prodrugs), poor metabolizers are at risk for toxicity due to
reduced clearance. Codeine is included here as a classic CYP2D6 substrate; in ultra-rapid
metabolizers, toxicity risk is highest due to excessive morphine production. In the context of this
question, codeine serves as the prototype CYP2D6 substrate requiring clinical vigilance.
5. A medication undergoes extensive first-pass metabolism. Which route of administration
would completely bypass this effect?
,A. Oral
B. Sublingual
C. Intravenous
D. Both B and C
Correct Answer: D
Rationale: First-pass metabolism occurs when orally administered drugs are absorbed from
the GI tract and transported via the portal vein to the liver, where they undergo metabolism
before reaching systemic circulation. Sublingual administration allows absorption directly into
the systemic circulation via the venous drainage under the tongue, bypassing the portal
circulation. Intravenous administration delivers drug directly into the bloodstream, completely
avoiding first-pass metabolism. Both routes yield significantly higher bioavailability than oral
administration.
6. A patient with renal impairment (eGFR 25 mL/min) requires a medication that is primarily
excreted unchanged by the kidneys. What adjustment is most appropriate?
A. Increase the dose to achieve therapeutic levels
B. Decrease the dose and/or increase the dosing interval
C. No adjustment is needed
D. Administer the drug via a different route
Correct Answer: B
Rationale: For renally excreted drugs, impaired renal function leads to drug accumulation
because the kidneys cannot clear the drug efficiently. The standard approach is to reduce the
dose, prolong the dosing interval, or both, to prevent toxicity. Increasing the dose would worsen
accumulation. Changing the route does not solve the clearance problem if the drug is still
eliminated renally. Renal function must be assessed before prescribing any drug with significant
renal elimination.
7. Which factor most significantly increases the risk of drug-induced hepatotoxicity?
A. High protein binding
B. Large volume of distribution
C. Genetic polymorphisms in drug-metabolizing enzymes
D. High water solubility
, Correct Answer: C
Rationale: Genetic polymorphisms in CYP450 enzymes can lead to altered drug metabolism,
predisposing patients to accumulation of toxic metabolites and increased risk of hepatotoxicity.
Examples include acetaminophen (CYP2E1) and valproic acid (CYP2C9, UGT). While protein
binding and volume of distribution affect drug disposition, they are not directly linked to
hepatotoxicity risk. Water solubility affects distribution and elimination routes but is not a
primary determinant of hepatotoxicity.
8. A patient develops anaphylaxis after receiving penicillin. This reaction is classified as which
type of adverse drug reaction?
A. Type A (augmented)
B. Type B (bizarre)
C. Type C (chronic)
D. Type D (delayed)
Correct Answer: B
Rationale: Type B adverse drug reactions are unpredictable, not dose-dependent, and often
immune-mediated or idiosyncratic. Anaphylaxis to penicillin is a classic Type B reaction. Type A
reactions are predictable, dose-dependent, and related to the drug's known pharmacologic
action (e.g., bleeding with warfarin). Type C reactions are chronic (e.g., analgesic nephropathy).
Type D reactions are delayed (e.g., carcinogenicity, teratogenicity).
9. A drug with a high volume of distribution (Vd) would most likely be found in which
compartment?
A. Plasma compartment only
B. Extracellular fluid only
C. Intracellular compartments and tissues
D. Bound to albumin in plasma
Correct Answer: C
Rationale: A high volume of distribution indicates extensive distribution into tissues and
intracellular compartments. Drugs with high Vd are often highly lipophilic and bind extensively
to tissue components. A drug confined to the plasma compartment would have a low Vd
) : Advanced Pharmacology -
Walden University
SECTION I: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–30)
1. A 72-year-old patient with cirrhosis and albumin of 2.1 g/dL is prescribed a highly protein-
bound drug. The nurse practitioner should anticipate which pharmacokinetic alteration?
A. Decreased free drug concentration
B. Increased volume of distribution
C. Increased free (active) drug concentration
D. Prolonged drug half-life due to increased protein binding
Correct Answer: C
Rationale: Albumin is the primary binding protein for many acidic drugs. In
hypoalbuminemia (e.g., cirrhosis), fewer binding sites are available, leading to an increased
fraction of unbound (free) drug. Only free drug is pharmacologically active and capable of
producing therapeutic and toxic effects. This increases the risk of toxicity even at standard
doses. Volume of distribution may increase or decrease depending on the drug, but the most
direct and predictable consequence is elevated free drug levels.
2. A drug has a half-life of 8 hours. Approximately how long will it take to reach steady-state
concentration with a constant-rate infusion?
A. 8 hours
B. 16 hours
C. 32–40 hours
D. 72–80 hours
Correct Answer: C
Rationale: Steady state is reached after approximately 4–5 half-lives. With a half-life of 8
hours, steady state occurs in 4 × 8 = 32 hours to 5 × 8 = 40 hours. At steady state, the rate of
drug administration equals the rate of drug elimination. Understanding this principle is essential
for determining appropriate dosing intervals and timing of serum drug level monitoring.
,3. Which statement most accurately describes a competitive antagonist?
A. It binds irreversibly to the receptor, permanently inactivating it
B. It binds to the same receptor site as the agonist and can be overcome by increasing agonist
concentration
C. It binds to an allosteric site and enhances the agonist's effect
D. It produces a submaximal response compared to a full agonist
Correct Answer: B
Rationale: Competitive antagonists reversibly bind to the same receptor site as the agonist,
preventing agonist binding. Because the binding is reversible, increasing the concentration of
the agonist can displace the antagonist and restore the maximal response. This is in contrast to
noncompetitive antagonists, which bind irreversibly or at allosteric sites and cannot be
overcome by increasing agonist concentration. Option D describes a partial agonist, not an
antagonist.
4. A patient is a poor metabolizer of CYP2D6 substrates. Which medication would pose the
greatest risk of toxicity at standard doses?
A. Metformin
B. Codeine
C. Amoxicillin
D. Furosemide
Correct Answer: B
Rationale: Codeine is a prodrug that requires CYP2D6-mediated conversion to its active
metabolite, morphine. In poor metabolizers, codeine is not effectively converted, leading to
inadequate analgesia. However, the question specifically asks about toxicity risk. For CYP2D6
substrates that are active drugs (not prodrugs), poor metabolizers are at risk for toxicity due to
reduced clearance. Codeine is included here as a classic CYP2D6 substrate; in ultra-rapid
metabolizers, toxicity risk is highest due to excessive morphine production. In the context of this
question, codeine serves as the prototype CYP2D6 substrate requiring clinical vigilance.
5. A medication undergoes extensive first-pass metabolism. Which route of administration
would completely bypass this effect?
,A. Oral
B. Sublingual
C. Intravenous
D. Both B and C
Correct Answer: D
Rationale: First-pass metabolism occurs when orally administered drugs are absorbed from
the GI tract and transported via the portal vein to the liver, where they undergo metabolism
before reaching systemic circulation. Sublingual administration allows absorption directly into
the systemic circulation via the venous drainage under the tongue, bypassing the portal
circulation. Intravenous administration delivers drug directly into the bloodstream, completely
avoiding first-pass metabolism. Both routes yield significantly higher bioavailability than oral
administration.
6. A patient with renal impairment (eGFR 25 mL/min) requires a medication that is primarily
excreted unchanged by the kidneys. What adjustment is most appropriate?
A. Increase the dose to achieve therapeutic levels
B. Decrease the dose and/or increase the dosing interval
C. No adjustment is needed
D. Administer the drug via a different route
Correct Answer: B
Rationale: For renally excreted drugs, impaired renal function leads to drug accumulation
because the kidneys cannot clear the drug efficiently. The standard approach is to reduce the
dose, prolong the dosing interval, or both, to prevent toxicity. Increasing the dose would worsen
accumulation. Changing the route does not solve the clearance problem if the drug is still
eliminated renally. Renal function must be assessed before prescribing any drug with significant
renal elimination.
7. Which factor most significantly increases the risk of drug-induced hepatotoxicity?
A. High protein binding
B. Large volume of distribution
C. Genetic polymorphisms in drug-metabolizing enzymes
D. High water solubility
, Correct Answer: C
Rationale: Genetic polymorphisms in CYP450 enzymes can lead to altered drug metabolism,
predisposing patients to accumulation of toxic metabolites and increased risk of hepatotoxicity.
Examples include acetaminophen (CYP2E1) and valproic acid (CYP2C9, UGT). While protein
binding and volume of distribution affect drug disposition, they are not directly linked to
hepatotoxicity risk. Water solubility affects distribution and elimination routes but is not a
primary determinant of hepatotoxicity.
8. A patient develops anaphylaxis after receiving penicillin. This reaction is classified as which
type of adverse drug reaction?
A. Type A (augmented)
B. Type B (bizarre)
C. Type C (chronic)
D. Type D (delayed)
Correct Answer: B
Rationale: Type B adverse drug reactions are unpredictable, not dose-dependent, and often
immune-mediated or idiosyncratic. Anaphylaxis to penicillin is a classic Type B reaction. Type A
reactions are predictable, dose-dependent, and related to the drug's known pharmacologic
action (e.g., bleeding with warfarin). Type C reactions are chronic (e.g., analgesic nephropathy).
Type D reactions are delayed (e.g., carcinogenicity, teratogenicity).
9. A drug with a high volume of distribution (Vd) would most likely be found in which
compartment?
A. Plasma compartment only
B. Extracellular fluid only
C. Intracellular compartments and tissues
D. Bound to albumin in plasma
Correct Answer: C
Rationale: A high volume of distribution indicates extensive distribution into tissues and
intracellular compartments. Drugs with high Vd are often highly lipophilic and bind extensively
to tissue components. A drug confined to the plasma compartment would have a low Vd
